Can IFN-γ be a therapeutic target in Guillain-Barré syndrome?

Bibliography

• van Doorn PA, Ruts L, Jacobs BC. Clinical features, pathogenesis, and treatment of Guillain-Barré syndrome. Lancet Neurol 2008;7:939-50
   PubMed Web of Science ®Google Scholar
• Hughes RA, Cornblath DR. Guillain-Barré syndrome. Lancet 2005;366:1653-66
   PubMed Web of Science ®Google Scholar
• Dilley A, Gregson NA, Hadden RD, et al. Effects on axonal conduction of anti-ganglioside sera and sera from patients with Guillain-Barre syndrome. J Neuroimmunol 2003;139:133-40
   PubMed Web of Science ®Google Scholar
• Chiba A, Kusunoki S, Shimizu T, et al. Serum IgG antibody to ganglioside GQ1b is a possible marker of Miller Fisher syndrome. Ann Neurol 1992;31:677-9
   PubMed Web of Science ®Google Scholar
• Sekiguchi Y, Uncini A, Yuki N, et al. Antiganglioside antibodies are associated with axonal Guillain-Barré syndrome: a Japanese-Italian collaborative study. J Neurol Neurosurg Psychiatry 2012;83:23-8
   PubMed Web of Science ®Google Scholar
• Hughes RA, Hadden RD, Gregson NA, et al. Pathogenesis of Guillain-Barré syndrome. J Neuroimmunol 1999;100:74-97
   PubMed Web of Science ®Google Scholar
• Sheikh KA, Zhang G, Gong Y, et al. An anti-ganglioside antibody-secreting hybridoma induces neuropathy in mice. Ann Neurol 2004;56:228-39
   PubMed Web of Science ®Google Scholar
• Tatsumoto M, Koga M, Gilbert M, et al. Spectrum of neurological diseases associated with antibodies to minor gangliosides GM1b and GalNAc-GD1a. J Neuroimmunol 2006;177:201-8
   PubMed Web of Science ®Google Scholar
• Lehrich JR, Arnason BG. Suppression of experimental allergic neuritis in rats by prior immunization with nerve in saline. Acta Neuropathol 1971;18:144-9
   PubMedGoogle Scholar
• Boehm U, Klamp T, Groot M, et al. Cellular responses to interferon-gamma. Annu Rev Immunol 1997;15:749-95
   PubMed Web of Science ®Google Scholar
• Schoenborn JR, Wilson CB. Regulation of interferon-gamma during innate and adaptive immune responses. Adv Immunol 2007;96:41-101
   PubMed Web of Science ®Google Scholar
• Hill N, Sarvetnick N. Cytokines: promoters and dampeners of autoimmunity. Curr Opin Immunol 2002;14:791-7
   PubMed Web of Science ®Google Scholar
• Skurkovich B, Skurkovich S. Inhibition of IFN-gamma as a method of treatment of various autoimmune diseases, including skin diseases. Ernst Schering Res Found Workshop 2006(56):1-27
   PubMedGoogle Scholar
• Lu MO, Zhu J. The role of cytokines in Guillain-Barré syndrome. J Neurol 2011;258:533-48
   PubMed Web of Science ®Google Scholar
• Hohnoki K, Inoue A, Koh CS. Elevated serum levels of IFN-gamma, IL-4 and TNF-alpha/unelevated serum levels of IL-10 in patients with demyelinating diseases during the acute stage. J Neuroimmunol 1998;87:27-32
   PubMed Web of Science ®Google Scholar
• Zhu J, Mix E, Link H. Cytokine production and the pathogenesis of experimental autoimmune neuritis and Guillain-Barré syndrome. J Neuroimmunol 1998;84:40-52
   PubMed Web of Science ®Google Scholar
• Skurkovich B, Skurkovich S. Anti-interferon-gamma antibodies in the treatment of autoimmune diseases. Curr Opin Mol Ther 2003;5:52-7
   PubMedGoogle Scholar
• Zhang HL, Zheng XY, Zhu J. Th1/Th2/Th17/Treg cytokines in Guillain-Barré syndrome and experimental autoimmune neuritis. Cytokine Growth Factor Rev 2013;24:443-53
   PubMed Web of Science ®Google Scholar
• Nyati KK, Prasad KN, Rizwan A, et al. TH1 and TH2 response to Campylobacter jejuni antigen in Guillain-Barre syndrome. Arch Neurol 2011;68:445-52
   PubMed Web of Science ®Google Scholar
• Horiuchi I, Ochi H, Murai H, et al. Th2 shift in mononeuritis multiplex and increase of Th2 cells in chronic inflammatory demyelinating polyneuropathy: an intracellular cytokine analysis. J Neurol Sci 2001;193:49-52
   PubMedGoogle Scholar
• McCombe PA, Csurhes PA. T cells from patients with Guillain-Barré syndrome produce interferon-gamma in response to stimulation with the ganglioside GM1. J Clin Neurosci 2010;17:537-8
   PubMedGoogle Scholar
• Huang S, Li L, Liang S, et al. Conversion of peripheral CD4(+)CD25(-) T cells to CD4(+)CD25(+) regulatory T cells by IFN-gamma in patients with Guillain-Barré syndrome. J Neuroimmunol 2009;217:80-4
   PubMedGoogle Scholar
• Liang SL, Wang WZ, Huang S, et al. Th17 helper cell and T-cell immunoglobulin and mucin domain 3 involvement in Guillain-Barré syndrome. Immunopharmacol Immunotoxicol 2012;34:1039-46
   PubMed Web of Science ®Google Scholar
• Steinman L. A brief history of T(H)17, the first major revision in the T(H)1/T(H)2 hypothesis of T cell-mediated tissue damage. Nat Med 2007;13:139-45
   PubMed Web of Science ®Google Scholar
• Elkarim RA, Dahle C, Mustafa M, et al. Recovery from Guillain-Barré syndrome is associated with increased levels of neutralizing autoantibodies to interferon-gamma. Clin Immunol Immunopathol 1998;88:241-8
   PubMedGoogle Scholar
• Dahle C, Kvarnstrom M, Ekerfelt C, et al. Elevated number of cells secreting transforming growth factor beta in Guillain-Barré syndrome. APMIS 2003;111:1095-104
   PubMedGoogle Scholar
• Press R, Ozenci V, Kouwenhoven M, et al. Non-T(H)1 cytokines are augmented systematically early in Guillain-Barré syndrome. Neurology 2002;58:476-8
   PubMed Web of Science ®Google Scholar
• Csurhes PA, Sullivan AA, Green K, et al. T cell reactivity to P0, P2, PMP-22, and myelin basic protein in patients with Guillain-Barré syndrome and chronic inflammatory demyelinating polyradiculoneuropathy. J Neurol Neurosurg Psychiatry 2005;76:1431-9
   PubMed Web of Science ®Google Scholar
• Dahle C, Ekerfelt C, Vrethem M, et al. T helper type 2 like cytokine responses to peptides from P0 and P2 myelin proteins during the recovery phase of Guillain-Barré syndrome. J Neurol Sci 1997;153:54-60
   PubMed Web of Science ®Google Scholar
• Aarli JA. Role of cytokines in neurological disorders. Curr Med Chem 2003;10:1931-7
   PubMed Web of Science ®Google Scholar
• Makowska A, Pritchard J, Sanvito L, et al. Immune responses to myelin proteins in Guillain-Barré syndrome. J Neurol Neurosurg Psychiatry 2008;79:664-71
   PubMed Web of Science ®Google Scholar
• Röcken M, Ravke M, Shevach EM. IL-4 induced immune deviation as antigen-specific therapy for inflammatory autoimmune diseases. Immunol Today 1996;17:225-31
   PubMedGoogle Scholar
• Miller CH, Maher SG, Young HA. Clinical Use of Interferon-gamma. Ann N Y Acad Sci 2009;1182:69-79
   PubMed Web of Science ®Google Scholar
• Zhang HL, Wu J, Zhu J. The role of apolipoprotein E in Guillain-Barré syndrome and experimental autoimmune neuritis. J Biomed Biotechnol 2010;2010:357412
   PubMedGoogle Scholar
• Argall KG, Armati PJ, Pollard JD, et al. Interactions between CD4+ T-cells and rat Schwann cells in vitro. 1. Antigen presentation by Lewis rat Schwann cells to P2-specific CD4+ T-cell lines. J Neuroimmunol 1992;40:1-18
   PubMedGoogle Scholar
• Duan RS, Jin T, Yang X, et al. Apolipoprotein E deficiency enhances the antigen-presenting capacity of Schwann cells. Glia 2007;55:772-6
   PubMedGoogle Scholar
• Linington C, Izumo S, Suzuki M, et al. A permanent rat T cell line that mediates experimental allergic neuritis in the Lewis rat in vivo. J Immunol 1984;133:1946-50
   PubMed Web of Science ®Google Scholar
• Brosnan JV, Craggs RI, King RH, et al. Reduced susceptibility of T cell-deficient rats to induction of experimental allergic neuritis. J Neuroimmunol 1987;14:267-82
   PubMedGoogle Scholar
• Zhu Y, Ljunggren H, Mix E, et al. CD28-B7 costimulation: a critical role for initiation and development of experimental autoimmune neuritis in C57BL/6 mice. J Neuroimmunol 2001;114:114-21
   PubMed Web of Science ®Google Scholar
• Hahn AF, Feasby TE, Gilbert JJ. Blood-nerve barrier studies in experimental allergic neuritis. Acta Neuropathol 1985;68:101-9
   PubMedGoogle Scholar
• Maurer M, Toyka KV, Gold R. Immune mechanisms in acquired demyelinating neuropathies: lessons from animal models. Neuromuscul Disord 2002;12:405-14
   PubMed Web of Science ®Google Scholar
• Köller H, Kieseier BC, Jander S, et al. Chronic inflammatory demyelinating polyneuropathy. N Engl J Med 2005;352:1343-56
   PubMed Web of Science ®Google Scholar
• Hadden RD, Gregson NA, Gold R, et al. Accumulation of immunoglobulin across the 'blood-nerve barrier' in spinal roots in adoptive transfer experimental autoimmune neuritis. Neuropathol Appl Neurobiol 2002;28:489-97
   PubMedGoogle Scholar
• Kiefer R, Kieseier BC, Stoll G, et al. The role of macrophages in immune-mediated damage to the peripheral nervous system. Prog Neurobiol 2001;64:109-27
   PubMed Web of Science ®Google Scholar
• Gratchev A, Kzhyshkowska J, Köthe K, et al. Mphi1 and Mphi2 can be re-polarized by Th2 or Th1 cytokines, respectively, and respond to exogenous danger signals. Immunobiology 2006;211:473-86
   PubMedGoogle Scholar
• Heusinkveld M, de Vos van Steenwijk PJ, Goedemans R, et al. M2 macrophages induced by prostaglandin E2 and IL-6 from cervical carcinoma are switched to activated M1 macrophages by CD4+ Th1 cells. J Immunol 2011;187:1157-65
   PubMed Web of Science ®Google Scholar
• Jung S, Huitinga I, Schmidt B, et al. Selective elimination of macrophages by dichlormethylenediphosphonate-containing liposomes suppresses experimental autoimmune neuritis. J Neurol Sci 1993;119:195-202
   PubMedGoogle Scholar
• Vriesendorp FJ, Flynn RE, Malone MR, et al. Systemic complement depletion reduces inflammation and demyelination in adoptive transfer experimental allergic neuritis. Acta Neuropathol 1998;95:297-301
   PubMedGoogle Scholar
• Stoll G, Schmidt B, Jander S, et al. Presence of the terminal complement complex (C5b-9) precedes myelin degradation in immune-mediated demyelination of the rat peripheral nervous system. Ann Neurol 1991;30:147-55
   PubMedGoogle Scholar
• Wohlleben G, Ibrahim SM, Schmidt J, et al. Regulation of Fas and FasL expression on rat Schwann cells. Glia 2000;30:373-81
   PubMedGoogle Scholar
• Jander S, Pohl J, Gillen C, et al. Differential expression of interleukin-10 mRNA in Wallerian degeneration and immune-mediated inflammation of the rat peripheral nervous system. J Neurosci Res 1996;43:254-9
   PubMed Web of Science ®Google Scholar
• Zhu J, Bai XF, Mix E, et al. Cytokine dichotomy in peripheral nervous system influences the outcome of experimental allergic neuritis: dynamics of mRNA expression for IL-1 beta, IL-6, IL-10, IL-12, TNF-alpha, TNF-beta, and cytolysin. Clin Immunol Immunopathol 1997;84:85-94
   PubMedGoogle Scholar
• Zhu J, Link H, Mix E, et al. Th1-like cell responses to peripheral nerve myelin components over the course of experimental allergic neuritis in Lewis rats. Acta Neurol Scand 1994;90:19-25
   PubMedGoogle Scholar
• Zhu J, Mix E, Olsson T, et al. Cellular mRNA expression of interferon-gamma, IL-4 and transforming growth factor-beta (TGF-beta) by rat mononuclear cells stimulated with peripheral nerve myelin antigens in experimental allergic neuritis. Clin Exp Immunol 1994;98:306-12
   PubMedGoogle Scholar
• Fujioka T, Jimi T, Hilliard BA, et al. The expression of cytokine mRNA in the cauda equina of Lewis rats with experimental allergic neuritis. J Neuroimmunol 1998;84:223-9
   PubMed Web of Science ®Google Scholar
• Lilje O, Armati PJ. Restimulation of resting autoreactive T cells by Schwann cells in vitro. Exp Mol Pathol 1999;67:164-74
   PubMedGoogle Scholar
• Gollob KJ, Coffman RL. A minority subpopulation of CD4+ T cells directs the development of naive CD4+ T cells into IL-4-secreting cells. J Immunol 1994;152:5180-8
   PubMedGoogle Scholar
• Schmidt B, Stoll G, van der Meide P, et al. Transient cellular expression of gamma-interferon in myelin-induced and T-cell line-mediated experimental autoimmune neuritis. Brain 1992;115:1633-46
   PubMedGoogle Scholar
• Hartung HP, Toyka KV. T-cell and macrophage activation in experimental autoimmune neuritis and Guillain–Barré syndrome. Ann Neurol 1990;27:S57-63
   PubMedGoogle Scholar
• Vriesendorp FJ, Flynn RE, Khan M, et al. Oral administration of type I interferon modulates the course of experimental allergic neuritis. Autoimmunity 1996;24:157-65
   PubMed Web of Science ®Google Scholar
• Hartung HP, Schäfer B, van der Meide PH, et al. The role of interferon-gamma in the pathogenesis of experimental autoimmune disease of the peripheral nervous system. Ann Neurol 1990;27:247-57
   PubMed Web of Science ®Google Scholar
• Zhu J, Bengtsson BO, Mix E, et al. Clomipramine and imipramine suppress clinical signs and T and B cell response to myelin proteins in experimental autoimmune neuritis in Lewis rats. J Autoimmun 1998;11:319-27
   PubMed Web of Science ®Google Scholar
• Bai XF, Shi FD, Zhu J, et al. Linomide-induced suppression of experimental autoimmune neuritis is associated with down-regulated macrophage functions. J Neuroimmunol 1997;76:177-84
   PubMed Web of Science ®Google Scholar
• Zhu J, Bai X, Mix E, et al. Thalidomide suppresses T- and B-cell responses to myelin antigen in experimental allergic neuritis. Clin Neuropharmacol 1997;20:152-64
   PubMed Web of Science ®Google Scholar
• Abbas N, Zou LP, Pelidou SH, et al. Protective effect of Rolipram in experimental autoimmune neuritis: protection is associated with down-regulation of IFN-gamma and inflammatory chemokines as well as up-regulation of IL-4 in peripheral nervous system. Autoimmunity 2000;32:93-9
   PubMed Web of Science ®Google Scholar
• Billiau A. Interferon-gamma in autoimmunity. Cytokine Growth Factor Rev 1996;7:25-34
   PubMedGoogle Scholar
• Andrews HJ, Bunning RA, Dinarello CA, et al. Modulation of human chrondrocyte metabolism by recombinant human interferongamma: in-vitro effects on basal and IL-1-stimulated proteinase production, cartilage degradation and DNA synthesis. Biochim Biophys Acta 1989;1012:128-34
   PubMedGoogle Scholar
• Zhu J, Zou LP, Bakhiet M, et al. Resistance and susceptibility to experimental autoimmune neuritis in Sprague-Dawley and Lewis rats correlate with different levels of autoreactive T and B cell responses to myelin antigens. J Neurosci Res 1998;54:373-81
   PubMedGoogle Scholar
• Zhang HL, Azimullah S, Zheng XY, et al. IFN-γ deficiency exacerbates experimental autoimmune neuritis in mice despite a mitigated systemic Th1 immune response. J Neuroimmunol 2012;246:18-26
   PubMed Web of Science ®Google Scholar
• Wang Z, Hong J, Sun W, et al. Role of IFN-gamma in induction of Foxp3 and conversion of CD4+ CD25 − T cells to CD4+ Tregs. J Clin Invest 2006;116:2434-41
   PubMed Web of Science ®Google Scholar
• ZhuY Ljunggren HG, Mix E, et al. Suppression of autoimmune neuritis in IFN-gamma receptor-deficient mice. Exp Neurol 2001;169:472-8
   PubMedGoogle Scholar
• Schattner A. Lymphokines in autoimmunity--a critical review. Clin Immunol Immunopathol 1994;70:177-89
   PubMedGoogle Scholar
• Zhang GX, Xiao BG, Bai XF, et al. Mice with IFN-gamma receptor deficiency are less susceptible to experimental autoimmune myasthenia gravis. J Immunol 1999;162:3775-81
   PubMed Web of Science ®Google Scholar
• Zhu Y, Ljunggren HG, Mix E, et al. Suppression of autoimmune neuritis in IFN-gamma receptor- deficient mice. Exp Neurol 2001;169:472-8
   PubMedGoogle Scholar
• Gollob KJ, Coffman RL. A minority subpopulation of CD4+ T cells directs the development of naive CD4+ T cells into IL-4-secreting cells. J Immunol 1994;152:5180-8
   PubMedGoogle Scholar
• Hsieh CS, Macatonia SE, O’Garra A, et al. Pathogen-induced Th1 phenotype development in CD4+ alpha beta-TCR transgenic T cells is macrophage dependent. Int Immunol 1993;5:371-82
   PubMedGoogle Scholar
• Seder RA, Paul WE. Acquisition of lymphokine-producing phenotype by CD4+ T cells. Annu Rev Immunol 1994;12:635-73
   PubMed Web of Science ®Google Scholar
• Weinberg AD, English M, Swain SL. Distinct regulation of lymphokine production is found in fresh versus in vitro primed murine helper T cells. J Immunol 1990;144:1800-16
   PubMedGoogle Scholar
• Zhu J, Mix E, Link H. Cytokine production and the pathogenesis of experimental autoimmune neuritis and Guillain–Barré syndrome. J Neuroimmunol 1998;84:40-52
   PubMed Web of Science ®Google Scholar
• Kaltsonoudis E, Voulgari PV, Konitsiotis S, et al. Demyelination and other neurological adverse events after anti-TNF therapy. Autoimmun Rev 2014;13:54-8
   PubMed Web of Science ®Google Scholar